Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29516484 | 1.00 | KMT2A (0.42) | KMT2AFABP5FABP7CASP3MDM2 | |
| SCHEMBL12314878 | 0.92 | KMT2A (0.41) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL30983406 | 0.92 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3MDM2 | |
| SCHEMBL30278742 | 0.91 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3MDM2 | |
| SCHEMBL22091999 | 0.91 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3MDM2 | |
| SCHEMBL29521277 | 0.90 | KMT2A (0.41) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL16060098 | 0.90 | KMT2A (0.41) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL31000664 | 0.89 | KMT2A (0.36) | KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL22092037 | 0.88 | KMT2A (0.39) | KMT2AFABP5FABP7MDM2EPHX2 | |
| SCHEMBL31688637 | 0.86 | KMT2A (0.36) | KMT2AFABP5FABP7CASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509502-B2 | Hybrid immunoglobulin containing nonpeptidyl linkage | BIOMOLECULAR HOLDINGS LLC (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4169944-A1 | PROCESS FOR PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | Biomolecular Holdings LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220275108-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC (US) | 2022-09-01 | — | — | US | disclosed |
| EP-4039281-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | Biomolecular Holdings LLC (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-3701971-B1 | COMPOUNDS USEFUL IN PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11220556-B2 | Hybrid immunoglobulin containing non-peptidyl linkage | BIOMOLECULAR HOLDINGS LLC (US) | 2022-01-11 | — | — | US | disclosed |
| EP-3611180-B1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210340222-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NONPEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC (US) | 2021-11-04 | — | — | US | disclosed |
| US-11066459-B2 | Hybrid immunoglobulin containing non-peptidyl linkage | BIOMOLECULAR HOLDINGS LLC (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3701971-A1 | COMPOUNDS USEFUL IN PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | Capon, Daniel J. (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-3611180-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | Capon, Daniel J. (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-2968495-B1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | CAPON DANIEL J (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-3116486-A2 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | Capon, Daniel J. (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20170008950-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC | 2017-01-12 | — | — | US | disclosed |
| US-20160024226-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC | 2016-01-28 | — | — | US | disclosed |
| WO-2015138907-A2 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | CAPON DANIEL J (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20030124053-A1 | Radiopharmaceuticals for imaging infection and inflammation | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066459-B2 | Hybrid immunoglobulin containing non-peptidyl linkage | FCGR3B, FCGR2A, SCLY | KMT2A 3227/4885FABP5 125/4885FABP7 308/4885 |
| US-20220275108-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | FCGR3B, FCGR2A, VSIG8 | KMT2A 2199/4885FABP5 1022/4885FABP7 903/4885 |
| US-11220556-B2 | Hybrid immunoglobulin containing non-peptidyl linkage | FCGR3B, FCGR2A, VSIG8 | KMT2A 1597/4885FABP5 1430/4885FABP7 1513/4885 |
| US-20030124053-A1 | Radiopharmaceuticals for imaging infection and inflammation | LTB4R, LTB4R2, LTA4H | KMT2A 4348/4885FABP5 249/4885FABP7 233/4885 |
| US-20210340222-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NONPEPTIDYL LINKAGE | FCGR3B, FCGR2A, SCLY | KMT2A 3177/4885FABP5 95/4885FABP7 271/4885 |
| US-20160024226-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | FCGR3B, FCGR2A, VSIG8 | KMT2A 2199/4885FABP5 1022/4885FABP7 903/4885 |
| US-20170008950-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | FCGR3B, SCLY, FCGR2A | KMT2A 2998/4885FABP5 148/4885FABP7 314/4885 |
| US-12509502-B2 | Hybrid immunoglobulin containing nonpeptidyl linkage | FCGR2A, FCGR3B, CD74 | KMT2A 3327/4885FABP5 66/4885FABP7 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.